Simplification to Efavirenz-TDF-FTC

STUDY 073
Simplification to Efavirenz-TDF-FTC Study 073: Study Design

**Background**: Randomized, controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed on baseline ART by switching to a single-tablet regimen of efavirenz-tenofovir DF-emtricitabine once daily

**Inclusion Criteria (n = 300)**
- Age ≥18 years
- HIV RNA ≤200 copies/mL for ≥3 months
- No new AIDS-defining conditions in past 30 days
- On 1st ART regimen or viral suppression on previous protease inhibitor-based therapy at time of prior therapy switch

**Treatment Arms**
- Switch arm: Efavirenz-tenofovir DF-emtricitabine
- Stay arm: maintain baseline ART

Simplification to Efavirenz-TDF-FTC
Study 073: Results

Week 48 Virologic Response by RNA Threshold

Simplification to Efavirenz-TDF-FTC
Study 073: Subgroup Analysis Result

Week 48 Virologic Response, by Baseline Regimen (Intent-to-Treat, Noncompletion = Failure)

Interpretation: “Simplification to EFV/FTC/TDF maintained high and comparable rates of virologic suppression versus stay on baseline regimen (SBR) through 48 weeks.”
Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.